Tag: O’Melveny & Myers
Samsung Biologics set to acquire PolyPeptide for USD1.8bn
Firms act on Samsung Biologics’ proposed CHF1.46 billion (USD1.8 billion) acquisition of Switzerland-based PolyPeptide Group
O’Melveny Aditya Kurian goes solo, starts Accord Partners
Former O’'Melveny & Myers’ counsel Aditya Kurian has launched independent practice, Accord Partners, to focus on international disputes and arbitration
O’Melveny & Myers boosts cross-border capabilities in Asia
O’Melveny hires John Curran as Corporate Finance Partner in Singapore to expand Asia presence
O’Melveny & Myers exits Japan as Tokyo head retires
O’Melveny & Myers is closing its Tokyo office after nearly 40 years, with Tokyo head Yoji Maeda set to retire
India rising, borders fading
As India expands its global trade ties and modernises its legal framework, international law firms are racing to keep pace
O’Melveny grows Singapore team with M&A hires
O'Melveny & Myers hires Stephanie Keen and Sylvia Taslim in Singapore to boost its M&A practice
Skadden boosts Asia disputes practice with new head
Skadden appoints Friven Yeoh as head of Asia litigation and arbitration, joining from Sidley Austin
Full speed ahead
India Business Law Journal is pleased to present its selection of the top 15 foreign law firms for India-related work
O’Melveny, Goodwin, White & Case in Samsung-eMagin merger
Three firms counsel Samsung Display and NYSE-listed eMagin in an agreement for the subsidiary of Samsung Electronics specialising in display products to acquire the American company for a USD218 million cash merger
Proposed A&O, Shearman merger sets legal market abuzz in Asia
Firms remain tight-lipped ahead of vote to approve move, but experts say talent retention and reassuring partners and clients tops agenda
Sinovac gets a shot in the arm
US law firm O’Melveny & Myers represented UBS Securities and Piper Jaffray as joint book-running managers in the US$66 million follow-on public offering of NASDAQ-listed Sinovac Biotech in February
